{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360290617631708800.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1080/03007995.2020.1816537"}},{"identifier":{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1816537"}},{"identifier":{"@type":"DOI","@value":"10.6084/m9.figshare.12903963"}},{"identifier":{"@type":"DOI","@value":"10.6084/m9.figshare.12903963.v1"}},{"identifier":{"@type":"PMID","@value":"32870712"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04"}],"description":[{"notation":[{"@value":"We conducted a head-to-head randomized trial of minodronate, a bisphosphonate, and raloxifene, a selective estrogen receptor modulator, to obtain clinical evidence and information about their efficacy and safety. The Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-04) trial is a multi-center, open-labeled, blinded endpoints, head-to-head randomized trial of minodronate and raloxifene. Ambulatory elderly women with osteoporosis (age, >60 years) were randomly allocated to the raloxifene or minodronate group by central registration. The co-primary endpoints included any one of osteoporotic fractures (vertebral, humeral, femoral, and radial fractures), vertebral fractures, and major osteoporotic fractures (clinical vertebral, humeral, femoral, and radial fractures). The biological effects of each drug, patients’ quality of life, and drug safety were assessed based on the secondary outcomes. This study was registered at the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) under trial identification number UMIN000005433. A total of 3896 patients were randomized to the minodronate and raloxifene groups, and drug efficacy assessments were performed for 3247 patients (1623 and 1624 patients, respectively). Among these patients, 1176 and 1187 patients received allocated treatment for 2 years. The incidence rate ratios for osteoporotic, vertebral, and major osteoporotic fractures in the minodronate group were 0.94 (95% CI: 0.78–1.13, <i>p</i> = .494), 0.86 (95% CI: 0.70–1.05, <i>p</i> = .147), and 1.22 (95% CI: 0.86–1.74, <i>p</i> = .274), respectively. Compared to the raloxifene group, the minodronate group showed significantly increased bone mineral density of the lumbar spine for each visit (6 months: <i>p</i> = .007, 12 months: <i>p</i> = .0003, 24 months: <i>p</i> Overall, there were no statistical differences in the incidence rates of osteoporotic, vertebral, or major osteoporotic fractures between the two groups. Serious adverse reactions were rare in both groups."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420564276189698560","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"80548537"},{"@type":"NRID","@value":"1000080548537"},{"@type":"NRID","@value":"9000259322241"},{"@type":"NRID","@value":"9000394955087"},{"@type":"NRID","@value":"9000238225147"},{"@type":"NRID","@value":"9000396162823"},{"@type":"NRID","@value":"9000415412816"},{"@type":"NRID","@value":"9000399361905"},{"@type":"NRID","@value":"9000401506153"},{"@type":"NRID","@value":"9000404537343"},{"@type":"NRID","@value":"9000377395257"},{"@type":"NRID","@value":"9000257999190"},{"@type":"NRID","@value":"9000388456476"},{"@type":"NRID","@value":"9000409789055"},{"@type":"NRID","@value":"9000398458014"},{"@type":"NRID","@value":"9000411393582"},{"@type":"NRID","@value":"9000314067157"},{"@type":"NRID","@value":"9000402395099"},{"@type":"NRID","@value":"9000399255128"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/yuemura"}],"foaf:name":[{"@value":"Yukari Uemura"}],"jpcoar:affiliationName":[{"@value":"Department of Data Science, Biostatistics Section, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708800","@type":"Researcher","foaf:name":[{"@value":"Teruki Sone"}],"jpcoar:affiliationName":[{"@value":"Department of Nuclear Medicine, Kawasaki Medical School, Okayama, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708807","@type":"Researcher","foaf:name":[{"@value":"Teruhiko Miyazaki"}],"jpcoar:affiliationName":[{"@value":"Public Health Research Foundation, Tokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708930","@type":"Researcher","foaf:name":[{"@value":"Mayumi Tsukiyama"}],"jpcoar:affiliationName":[{"@value":"Public Health Research Foundation, Tokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708933","@type":"Researcher","foaf:name":[{"@value":"Shiro Tanaka"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Biostatistics, Graduate School of Medicine Kyoto University, Kyoto, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708803","@type":"Researcher","foaf:name":[{"@value":"Satoshi Soen"}],"jpcoar:affiliationName":[{"@value":"Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kindai University, Nara, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1420845751142589568","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70243582"},{"@type":"NRID","@value":"1000070243582"},{"@type":"NDL_AUTHOR_ID","@value":"001117867"},{"@type":"NRID","@value":"9000254174313"},{"@type":"NRID","@value":"9000256583606"},{"@type":"NRID","@value":"9000399749272"},{"@type":"NRID","@value":"9000254366196"},{"@type":"NRID","@value":"9000254619683"},{"@type":"NRID","@value":"9000254174088"},{"@type":"NRID","@value":"9000258692275"},{"@type":"NRID","@value":"9000267776510"},{"@type":"NRID","@value":"9000254174051"},{"@type":"NRID","@value":"9000400183975"},{"@type":"NRID","@value":"9000311504519"},{"@type":"NRID","@value":"9000258383222"},{"@type":"NRID","@value":"9000403306490"},{"@type":"NRID","@value":"9000254174394"},{"@type":"NRID","@value":"9000391505285"},{"@type":"NRID","@value":"9000402937204"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0016688"}],"foaf:name":[{"@value":"Akira Taguchi"}],"jpcoar:affiliationName":[{"@value":"Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Nagano, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708806","@type":"Researcher","foaf:name":[{"@value":"Satoshi Mori"}],"jpcoar:affiliationName":[{"@value":"Bone and Joint Surgery, Seirei Hamamatu General Hospital, Shizuoka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708931","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Hagino"}],"jpcoar:affiliationName":[{"@value":"School of Health Science, Tottori University faculty of Medicine, Tottori, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708802","@type":"Researcher","foaf:name":[{"@value":"Toshitsugu Sugimoto"}],"jpcoar:affiliationName":[{"@value":"Eikokai Ono Hospital, Hyogo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708934","@type":"Researcher","foaf:name":[{"@value":"Masao Fukunaga"}],"jpcoar:affiliationName":[{"@value":"Department of Nuclear Medicine, Kawasaki Medical School, Okayama, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708804","@type":"Researcher","foaf:name":[{"@value":"Hiroaki Ohta"}],"jpcoar:affiliationName":[{"@value":"International Medical Center, Fujita Health University, Aichi, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708928","@type":"Researcher","foaf:name":[{"@value":"Toshitaka Nakamura"}],"jpcoar:affiliationName":[{"@value":"Japan Osteoporosis Foundation, Tokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708932","@type":"Researcher","foaf:name":[{"@value":"Masataka Shiraki"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380290617631708929","@type":"Researcher","foaf:name":[{"@value":"Hajime Orimo"}],"jpcoar:affiliationName":[{"@value":"Japan Osteoporosis Foundation, Tokyo, Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03007995"},{"@type":"EISSN","@value":"14734877"}],"prism:publicationName":[{"@value":"Current Medical Research and Opinion"}],"dc:publisher":[{"@value":"Informa UK Limited"}],"prism:publicationDate":"2020-09-14","prism:volume":"36","prism:number":"11","prism:startingPage":"1847","prism:endingPage":"1859"},"reviewed":"false","url":[{"@id":"https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1816537"}],"createdAt":"2020-09-01","modifiedAt":"2021-03-22","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Bone%20Density%20Conservation%20Agents","dc:title":"Bone Density Conservation Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Diphosphonates","dc:title":"Diphosphonates"},{"@id":"https://cir.nii.ac.jp/all?q=Incidence","dc:title":"Incidence"},{"@id":"https://cir.nii.ac.jp/all?q=Imidazoles","dc:title":"Imidazoles"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Bone%20Density","dc:title":"Bone Density"},{"@id":"https://cir.nii.ac.jp/all?q=Raloxifene%20Hydrochloride","dc:title":"Raloxifene Hydrochloride"},{"@id":"https://cir.nii.ac.jp/all?q=Quality%20of%20Life","dc:title":"Quality of Life"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Osteoporosis,%20Postmenopausal","dc:title":"Osteoporosis, Postmenopausal"},{"@id":"https://cir.nii.ac.jp/all?q=Osteoporotic%20Fractures","dc:title":"Osteoporotic Fractures"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782001512320","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18K09758"},{"@type":"JGN","@value":"JP18K09758"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K09758/"}],"notation":[{"@language":"ja","@value":"口腔顎顔面画像指標による生活習慣病関連骨質劣化型骨折スクリーニング法の開発"},{"@language":"en","@value":"Development of screening system for identifying individuals with lifestyle-related fragility fractures by oral and maxillofacial image indices"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050287297275055616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360001114040544896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231279094912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144126042880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144773312512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Three years of treatment with minodronate in patients with postmenopausal osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145157049344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620863183872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181232467712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095380320896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096090587520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Benefits and Risks of Bisphosphonate Therapy for Osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569834919296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Homocysteine level and risk of fracture: A meta-analysis and systematic review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570523782144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A method to assess the proportion of treatment effect explained by a surrogate endpoint"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044996973696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta-Analyses"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518998390912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Predictive Value of BMD for Hip and Other Fractures"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520250108672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994384618496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995088842240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995435362688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996364408320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trreatment With Alendronate Prevents Fractures in Women at Highest Risk"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469388311040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of Bisphosphonate-related Osteonecrosis of the Jaw on Osteoporotic Patients after Dental Extraction: A Population-Based Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470057166976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470773347712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470841185664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944089792128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Homocysteine Levels and the Risk of Osteoporotic Fracture"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944717718016","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The role of ethnicity, age and gender in venous thromboembolism"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946000595072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419049417344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419268958208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419474020736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420355953920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893438969472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893868379776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacological treatment of osteoporosis in the oldest old"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894500756096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369138408960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bone Loss, Weight Loss, and Weight Fluctuation Predict Mortality Risk in Elderly Men and Women"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370103434624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Romosozumab in Postmenopausal Women with Low Bone Mineral Density"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370274369152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Noninvasive assessment of bone mineral and structure: State of the art"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843332834816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844143043072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844510752384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846253133824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846279879040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319151905920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320072445568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fractures in women treated with raloxifene or alendronate: a retrospective database analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268960052352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reducing hip fracture risk with risedronate in elderly women with established osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270784012288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1080/03007995.2020.1816537"},{"@type":"KAKEN","@value":"PRODUCT-23600905"},{"@type":"OPENAIRE","@value":"doi_dedup___::22a6bc9e5cc9981e9e75e989fe85f017"}]}